WOW is all I can say right now. The dork has been absolutely killing it for me recently. Check out this free service at the-stock*dork .
MEGA OPP on this one ... SLNO (MC $25 M) BLOCKBUSTER in Phase 3 /Rare Disease +Orphan Status /$2+ BILLION Market /NO Debt = REAL Unknown low float stock with 1000% upside Potential and more .Next billion dollar rare disease company like SRPT here .GLTA
Soleno therapeutics (SLNO)
Market Cap $25 Million Cash: $8 Million Price $0.51
Shares Out: 47.6 Million ( 36 Million shares held by Insiders & Institutions)
•Company expects to initiate pivotal Phase III clinical trial by year-end 2017; will take approximately 9-12 months to complete
Soleno Therapeutics, Inc. (Soleno) is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is currently advancing its lead candidate, DCCR, a once-daily oral tablet for the treatment of PWS, into a Phase III clinical development program at the end of 2017.
Market Opportunity for PWS is Substantial.
While the lack of approved treatments for PWS alone make it difficult to assess the market, sales of Pfizer’s (NYSE: PFE) Genotrop in (somatropin) can provide some insight despite being indicate for PWS, in addition to, growth failure due to growth hormone deficiency(GHD),Turner syndrome,idiopathic short stature,and small for gestational age.This product achieved its highest revenue in 2008,with worldwide sales of approximately $900 million.While somatropin has been proven to improve growth and body composition, it does not affect the key disease component of hyperphagia and use is associated with substantial risk. Soleno is developing DCCR for the treatment of PWS,to help address the unmet need of this patient population. To assess the potential of DCCR for PWS, we performed a scenario analysis, which indicates that annual sales could be in the range of $1.1 billion given a moderate price point and 50% market penetrance.
X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks May-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is 0.8 In other words, the correlation coefficient of the other stock
Things seem to be getting overextended for ILMN. awe-some*sto-cks recently alerted this company i think. google them.
ILMN stock keeps pushing to new highs, yet the insiders keep selling the stock during the climb up. Check out the awarded options and the automatic sales. Seems to me if the stock was reasonably priced, then the inside officers would want to hold on for a bigger profit later.
I think ILMN might have reached its upward limit and that a pullback may be possible. if you guys have questions you should ask https://hotstocks123.blogspot.com. They often respond to my emails which is helpful.
stock has rocketed from a low of 120 to more than 200 in a matter of 9 months. What has changed materially for ILMN to add so much to it's market cap?
Best MicroCap, Small Cap and Emerging Stocks to Buy - J Charles Assets
We search for the smart new growing companies to invest in with stock deals to watch in pharmacuetical and digital verticals.
Any guesses of where it'll move from here?
Earnings easily topped expectations.
AAPL and ILMN, romantic ideal couple.
Nice move up. OT Must see AVEO...close to moving up higher...come to the Yahoo message board. Rx for Renal cancer-Tivozanib- Recommended for Approval. Date for Approval end Aug...SOON.
down after hours?
Test kit is huge deal should bring significant move.
(AXSM) Market Cap $90 M/Cash $55 M / 5x BIG Phase 3 programs in various indications targeting large Markets with first results in Q3 2017 =20 BAGGER ..FANTASTIC OPPORTUNITY !
Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $90 million and $55 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .
This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL
Market-Cap: $90 Million Cash: $55 Million(cash runway into the first quarter of 2019.) Price:$3.90
Shares Out: 23.5 Million
Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) after the company reported financial results for the quarter ended March 31, 2017. The analyst noted that although Axsome reported revenue in-line with consensus estimates, the focus remains on upcoming catalysts such as the company’s ongoing clinical trials. Since February 2017, the company’s AXS-05 has received fast track designation from the FDA for the treatment of Alzheimer’s disease (AD) agitation and treatment resistant depression (TRD). Topline data from the TRD treatment study is expected in the first quarter of 2018. Additionally, Axsome is developing AXS-02 in three separate phase 3 clinical programs, including chronic low back pain associated with modic changes and complex regional pain syndrome, with interim data expected in the fourth quarter of 2017, as well as knee osteoarthritis associated with bone marrow lesions, with interim data expected in the third quarter of 2017.
Yahoo Finance Insights
ILMN is down -4.92% to 168.94
Wait, didn't this scam missed earnings and downwardly revised the guidance big time. Oh I forgot we are in the bubble so all that doesn't matter. But wait what will happen to #$%$ stocks like these when bubble finally goes bonker? It may happen starting Monday. Nasdaq wouldn't stop until it has falled 20-30% or more. Some are saying 80% drop, worst ever after 1929 and 2000.